A prospective, multicenter, non-interventional study evaluating effectiveness and safety of gueslkumab and ustekinumab in patients with moderate-to-severe plaque psoriasis in a German real-world setting
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Guselkumab (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PERSIST
- 12 Mar 2024 Results assessing BMI-subgroup outcomes over 2 years, presented at the American Academy of Dermatology annual Meeting 2024
- 01 Sep 2022 Results assessing the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in patients with moderate-to-severe psoriasis who have received 52 weeks of treatment, published in the Journal of the European Academy of Dermatology and Venereology.
- 01 Dec 2021 Results assessing effectiveness of guselkumab in patients with psoriasis published in the Journal of Dermatology